<![CDATA[Giredestrant/Everolimus Opens Doors for Improved SERD Regimens for ER+, Endocrine-Resistant Breast Cancer]]>
Giredestrant’s potency, favorable safety profile, and synergy with everolimus (Afinitor) in the phase 3 evERA trial (NCT05306340) underscore its promise as a next-generation oral selective estrogen receptor degrader (SERD) for patients with endocrine- …